Literature DB >> 18972544

Applause sign in Parkinsonian disorders and Huntington's disease.

Laura J C Wu1, Oraporn Sitburana, Anthony Davidson, Joseph Jankovic.   

Abstract

The applause sign has been previously reported to be indicative of neurodegenerative disorders, such as progressive supranuclear palsy (PSP). In order to determine the sensitivity, specificity, and positive predictive value, we tested it in patients with PSP, Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal degeneration (CBD), and Huntington's disease (HD). Subjects were asked to clap three times after demonstration by the examiner. The performance was scored as follows: 3 = claps only three times; 2 = claps four times; 1 = claps 5 to 10 times; 0 = claps >10 times. The clap test was videotaped and rated. Patients with CBD, MSA, and PSP showed significant differences in clap scores compared with normal controls. The test differentiated patients with CBD from those with PD (P < 0.005) and HD (P < 0.005), but failed to discriminate patients with PSP from other parkinsonian groups. The specificity of the applause sign is 100% in distinguishing parkinsonian patients from normal subjects with the highest sensitivity in CBD patients. We concluded that the applause sign is highly specific for parkinsonian disorders but it is not a specific sign for PSP; it appears to be most sensitive for CBD. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18972544     DOI: 10.1002/mds.22090

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  The applause sign in frontotemporal lobar degeneration and related conditions.

Authors:  Sonja Schönecker; Franz Hell; Kai Bötzel; Elisabeth Wlasich; Nibal Ackl; Christine Süßmair; Markus Otto; Sarah Anderl-Straub; Albert Ludolph; Jan Kassubek; Hans-Jürgen Huppertz; Janine Diehl-Schmid; Lina Riedl; Carola Roßmeier; Klaus Fassbender; Epameinondas Lyros; Johannes Kornhuber; Timo Jan Oberstein; Klaus Fliessbach; Anja Schneider; Matthias L Schroeter; Johannes Prudlo; Martin Lauer; Holger Jahn; Johannes Levin; Adrian Danek
Journal:  J Neurol       Date:  2018-12-01       Impact factor: 4.849

2.  Localisation of the applause sign in a patient with acute bilateral lenticular infarction.

Authors:  Richard A Walsh; Joe Duggan; Tim Lynch
Journal:  J Neurol       Date:  2011-01-26       Impact factor: 4.849

3.  Applause sign in Alzheimer's disease: relationships to cognitive profile and severity of illness.

Authors:  Simona Luzzi; Katia Fabi; Martina Pesallaccia; Mauro Silvestrini; Leandro Provinciali
Journal:  J Neurol       Date:  2012-07-20       Impact factor: 4.849

4.  Human wildtype tau expression in cholinergic pedunculopontine tegmental neurons is sufficient to produce PSP-like behavioural deficits and neuropathology.

Authors:  Gabriella King; Kaliana M Veros; Duncan Archibald Allan MacLaren; Martin Peter Konrad Leigh; Joseph A Spernyak; Stewart D Clark
Journal:  Eur J Neurosci       Date:  2021-11-02       Impact factor: 3.698

Review 5.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

6.  The applause sign in cortical and cortical-subcortical dementia.

Authors:  Valeria Isella; Francesco Rucci; Debora Traficante; Cristina Mapelli; Francesca Ferri; Ildebrando M Appollonio
Journal:  J Neurol       Date:  2012-12-02       Impact factor: 4.849

7.  Triple Test Plus Rapid Cognitive Screening Test: A Combination of Clinical Signs and A Tool for Cognitive Assessment in Older Adults.

Authors:  Saadet Koc Okudur; Ozge Dokuzlar; Derya Kaya; Pinar Soysal; Ahmet Turan Isik
Journal:  Diagnostics (Basel)       Date:  2019-08-15

8.  Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.

Authors:  Kristina A Neely; Peggy J Planetta; Janey Prodoehl; Daniel M Corcos; Cynthia L Comella; Christopher G Goetz; Kathleen L Shannon; David E Vaillancourt
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.